Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
This PSD-3, the first pharmaceutical spray dryer built by GEA for OEB-5 products, sets new standards for high-containment pharmaceutical spray drying
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Subscribe To Our Newsletter & Stay Updated
